Fanotaprim structure
|
Common Name | Fanotaprim | ||
---|---|---|---|---|
CAS Number | 2120282-75-7 | Molecular Weight | 378.43 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C19H22N8O | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of FanotaprimFanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC50s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis[1]. |
Name | Fanotaprim |
---|
Description | Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC50s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis[1]. |
---|---|
Related Catalog | |
In Vitro | Fanotaprim shows parasiticidal and antiproliferative effects with EC50s of 13 and 7300 nM against the type I RH strain of T. gondii and MCF-7 cells, respectively[1]. Fanotaprim shows ability to inhibit the growth of T. gondii strains in vitro with EC50s ranging 7.6~ 29.8 nM (GT1, ME49, CTG, RUB and VAND)[1]. |
In Vivo | Fanotaprim (1-10 mg/kg; p.o.; daily; beginning on day 1 through day 7) shows highly effective in control of acute infection by highly virulent strains of T. gondii in the murine model[1]. Fanotaprim (1mg/kg; i.v; mouse) shows CL, Vd, and t1/2 values of 10.6 mL/min/kg, 1.14 L/kg, and 3.9 hours, respectively[1]. Fanotaprim (0.83 mg/kg; p.o; mouse) shows F, Cmax, Tmax, and AUC0-last of 47.3%, 178 ng/mL, 0.05 hours and 750 ng h/mL, respectively[1]. Animal Model: CD-1female mice (murine model of acute toxoplasmosis)[1] Dosage: 1-10 mg/kg Administration: p.o.; daily; beginning on day 1 through day 7 Result: Mice were monitored for survival for 30 days within termittent IVIS monitoring. At doses of 10 mg/kg Fanotaprim, q.d. or b.i.d. for 7 days, yielded 100% survival for 30 days. |
References |
Molecular Formula | C19H22N8O |
---|---|
Molecular Weight | 378.43 |